Latest News

All Articles

Filter by:
Topic
Journal Club Journal Club

Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial

January 02, 2023

Olutasidenib, with or without azacitidine, was well tolerated and showed meaningful clinical activity in patients with IDH1-mutated acute myeloid leukaemia.

Education

Overcoming Challenges to Provide BiTE and CAR T Cell Therapy at a Community Cancer Center

December 31, 2022

Krista L. Voytilla, PharmD, BCOP, and Chase N. Ayres, PharmD, BCOP, review the technical and clinical issues facing community cancer centers and their pharmacy teams delivering these high-tech treatments.

Pharmacists talking
Education

Reaching the Melting Point: My Time Transitioning from a Solid to a Liquid Tumor Pharmacist

December 30, 2022

Reflection on Personal Impact and Growth

Imaging scan of lung cancer
Tools and Resources Drug Updates

Pharmacist Application to Practice: Adagrasib

December 22, 2022

Sam Palmatier, Pharmacy Intern and Jeff Engle, PharmD, MS, Oncology Pharmacy Manager at Fairview Cancer Clinic – Edina write about

Tools and Resources Drug Updates

Pharmacist's Application to Practice: Mosunetuzumab

December 22, 2022

Bernard Marini, PharmD, BCOP Clinical Pharmacist Specialist – Hematology/Oncology Clinical Associate Professor University of Michigan College of Pharmacy writes about Mosunetuzumab.

Drug Updates

Pharmacist's Application to Practice: Nadofaragene
firadenovec-vncg

December 16, 2022

Kelli Rourke, PharmD Clinical Pharmacy Specialist at The Johns Hopkins Hospital writes about nadofaragene firadenovec-vncg

Tools and Resources Drug Updates

Pharmacist's Application to Practice: Olutasidenib

December 01, 2022

Bernard Marini, PharmD, BCOP, Clinical Pharmacist at University of Michigan College of Pharmacy writes about Olutasidenib

Drug Updates

Pharmacist’s Application to Practice:
Mirvetuximab soravtansine-gynx

November 14, 2022

Shrina Patel, PharmD, BCOP, Clinical Pharmacy Specialist at University of Texas MD Anderson Cancer Center writes about Mirvetuximab soravtansine-gynx.

Scan of human lungs
Tools and Resources Drug Updates

Pharmacist's Application to Practice: Tremelimumab

November 10, 2022

Tremelimumab (IMJUDO, AztraZeneca Pharmaceuticals) approved November 10, 2022 for metastatic non-small cell lung cancer and approved October 24, 2022 for unresectable hepatocellular carcinoma

Tools and Resources Drug Updates

Pharmacist’s Application to Practice: Teclistamab-cqyv

October 25, 2022

Gavyn Walsh, PD3 Oncology Pharmacy Intern and Erin Kelley, PharmD, BCOP at M Health Fairview Masonic Cancer Clinic write about teclistamab-cqyv

Late Breaking News

Adapting Investigational Drug Services During a Pandemic

October 06, 2022

Recommendations for future preparedness from the Hematology/Oncology Pharmacy Association Investigational Drug Services Special Interest Group

Tools and Resources Drug Updates

Pharmacist's Application to Practice: Futibatinib

September 30, 2022

Mei Ka Fong, Pharm.D., BCOP Clinical Pharmacist Coordinator Levine Cancer Institute, Atrium Health writes about Futibatinib